---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-179093"
form_type: "8-K/A"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:50:40.600890+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImageneBio files Inmagene pre-merger financials: $13.7M loss, going concern, $6M cash

## Summary
- Inmagene net loss of $7.6M in Q2 2025 and $13.7M in first half 2025; accumulated deficit $197.5M.
- Cash and equivalents $6.0M at June 30, 2025; operating cash burn $19.1M in first half 2025.
- Management states substantial doubt about continuing as a going concern; cash insufficient for next 12 months.
- Term loan of $22.9M (6% interest, secured by IMG-007) automatically forgiven upon merger close July 25, 2025.
- Ikena concurrent financing of $75M contributed to fund IMG-007 development after merger.

## SEC filing metadata
- accession: 0001193125-25-179093
- form_type: 8-K/A
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312525179093/0001193125-25-179093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312525179093/d655327d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-179093
- JSON: https://secwatch.observer/filing/0001193125-25-179093.json
- Plain text: https://secwatch.observer/filing/0001193125-25-179093.txt

## Key facts
- M&A Transactions
  ImageneBio, Inc. underwent a change of control involving Inmagene Biopharmaceuticals (closed 2025-07-25).
  - Action: change of control
  - Counterparty: Inmagene Biopharmaceuticals
  - Closing: 2025-07-25
  source text: On July 25, 2025, the Delaware corporation formerly known as "Ikena Oncology, Inc." completed its previously announced merger with Inmagene Biopharmaceuticals, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands ("Inmagene"), in accordance with the terms of the Agreement and Plan of Merger, dated as of December 23, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312525179093/0001193125-25-179093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.